RT Journal Article SR Electronic T1 Improving Patient Selection for 18F-FDG PET Scanning in the Staging of Gastric Cancer JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 523 OP 529 DO 10.2967/jnumed.114.150946 VO 56 IS 4 A1 Yui Kaneko A1 William K Murray A1 Emma Link A1 Rodney J. Hicks A1 Cuong Duong YR 2015 UL http://jnm.snmjournals.org/content/56/4/523.abstract AB Standard pretreatment staging for gastric cancer includes CT of the chest, abdomen, and pelvis; gastroscopy; and laparoscopy. Although 18F-PET combined with CT has proven to be a useful staging tool in many cancers, some gastric cancers are not 18F-FDG–avid and its clinical value is still debatable. Methods: Gastric cancer patients who underwent staging 18F-FDG PET scans from 2002 to 2013 at the Peter MacCallum Cancer Center were retrospectively analyzed, and a systematic review was also conducted using PubMed between 2000 to March 2014 to investigate clinicopathologic parameters associated with 18F-FDG avidity. A pretreatment PET scoring system was developed from predictors of 18F-FDG avidity. Results: Both the retrospective analysis of the patients and the systematic literature review showed similar significant predictors of 18F-FDG avidity, including large tumor size, non–signet ring cell carcinoma type, and glucose transporter 1–positive expression on immunohistochemistry. A PET scoring system was developed from these clinicopathologic parameters that allowed 18F-FDG–avid tumors to be detected with a sensitivity of 85% and a specificity of 71%. Conclusion: A pretreatment PET scoring system can assist in the selection of patients with gastric adenocarcinoma when staging 18F-FDG PET is being considered.